GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lanzhou Foci Pharmaceutical Co Ltd (SZSE:002644) » Definitions » Capex-to-Operating-Cash-Flow

Lanzhou Foci Pharmaceutical Co (SZSE:002644) Capex-to-Operating-Cash-Flow : 0.97 (As of Mar. 2025)


View and export this data going back to 2011. Start your Free Trial

What is Lanzhou Foci Pharmaceutical Co Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Lanzhou Foci Pharmaceutical Co's Capital Expenditure for the three months ended in Mar. 2025 was ¥-7.85 Mil. Its Cash Flow from Operations for the three months ended in Mar. 2025 was ¥8.11 Mil.

Hence, Lanzhou Foci Pharmaceutical Co's Capex-to-Operating-Cash-Flow for the three months ended in Mar. 2025 was 0.97.


Lanzhou Foci Pharmaceutical Co Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Lanzhou Foci Pharmaceutical Co's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lanzhou Foci Pharmaceutical Co Capex-to-Operating-Cash-Flow Chart

Lanzhou Foci Pharmaceutical Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.95 2.77 0.48 0.34 0.34

Lanzhou Foci Pharmaceutical Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.59 - 0.08 0.97

Competitive Comparison of Lanzhou Foci Pharmaceutical Co's Capex-to-Operating-Cash-Flow

For the Drug Manufacturers - Specialty & Generic subindustry, Lanzhou Foci Pharmaceutical Co's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lanzhou Foci Pharmaceutical Co's Capex-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lanzhou Foci Pharmaceutical Co's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Lanzhou Foci Pharmaceutical Co's Capex-to-Operating-Cash-Flow falls into.


;
;

Lanzhou Foci Pharmaceutical Co Capex-to-Operating-Cash-Flow Calculation

Lanzhou Foci Pharmaceutical Co's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-13.29) / 38.985
=0.34

Lanzhou Foci Pharmaceutical Co's Capex-to-Operating-Cash-Flow for the quarter that ended in Mar. 2025 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-7.854) / 8.11
=0.97

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lanzhou Foci Pharmaceutical Co  (SZSE:002644) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Lanzhou Foci Pharmaceutical Co Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Lanzhou Foci Pharmaceutical Co's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Lanzhou Foci Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
68 Foci Street ChangGuan Region, Lanzhou, CHN, 730046
Lanzhou Foci Pharmaceutical Co Ltd is a pharmaceutical company based in China. The company is engaged in the production and sales of Chinese traditional medicine. In addition to manufacturing, the company also conducts research to develop new herbal drugs. Its product portfolio consists of concentrated pills, granules, hard capsules, concentrated decoctions and medicinal wine. The products of the company are exported to more than 27 countries including the United States, Canada, Japan, Australia, Russia, and Ukraine, among others.
Executives
Sun Yu Directors, executives
Su Wen Bo Supervisors
An Wen Ting Securities Affairs Representative

Lanzhou Foci Pharmaceutical Co Headlines

No Headlines